Bacterial Conjunctivitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively for Bacterial Conjunctivitis.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Conjunctivitis - Overview 7
Bacterial Conjunctivitis - Therapeutics under Development by Companies 8
Bacterial Conjunctivitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Bacterial Conjunctivitis - Products under Development by Companies 12
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 13
InSite Vision Incorporated 13
NovaBay Pharmaceuticals, Inc. 14
Shire Plc 15
Bacterial Conjunctivitis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 24
auriclosene - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
azithromycin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ISV-405 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SHP-640 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
vancomycin hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Bacterial Conjunctivitis - Dormant Projects 36
Bacterial Conjunctivitis - Product Development Milestones 37
Featured News & Press Releases 37
Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses 37
Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical 38
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 38
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 38
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 39
Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma 39
Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco 39
Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 40
Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 40
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for Bacterial Conjunctivitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H2 2016 13
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2016 14
Bacterial Conjunctivitis - Pipeline by Shire Plc, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 23
Bacterial Conjunctivitis - Dormant Projects, H2 2016 36